The Case Against Trump's Psychedelic Executive Order — And Why It Falls Short
A full written analysis of my debate with a former Obama/Bush drug policy advisor & renowned Johns Hopkins psychedelic researcher.
When President Trump signed an executive order accelerating federal action on psychedelic therapies, the response from many advocates was celebratory. For veterans, addiction patients, and people with treatment-resistant depression, the order looked like long-overdue recognition that America’s mental health crisis demands new tools.
But not everyone was convinced.
On my podcast, I debated the order with Dr. Kevin Sabet, a former drug policy advisor in the Obama, Bush, and Clinton administrations, and Dr. Matt Johnson, a psychiatry professor at Johns Hopkins and one of the world’s leading psychedelic researchers. Sabet is one of the most articulate critics of drug liberalization in America, and his critique deserves to be taken seriously. His core concern is not that psychedelic compounds have no medical potential. In fact, he repeatedly acknowledged that they may. His concern is that America may be “putting the cart before the horse”: allowing hype, politics, celebrity influence, Silicon Valley investment, and desperation to outrun the science.
The executive order, signed on April 18, directs the FDA to prioritize certain psychedelic drugs with Breakthrough Therapy designation, helps create a pathway for eligible patients to access investigational psychedelics under Right to Try, and calls for support for research, including ibogaine compounds. The FDA soon announced National Priority Vouchers for three psychedelic-related programs, a mechanism intended to speed review timelines while maintaining safety and efficacy standards.
Sabet’s argument is the best version of the skeptical case: psychedelics may help some people, but the culture around them is moving too quickly, too emotionally, and too commercially. But after pressing each of his objections one by one, I came away believing that the executive order is far more modest — and far more defensible — than its critics suggest.
1. “The psilocybin depression studies are weaker than advocates admit”
Sabet’s first major argument was that the evidence base for psychedelics, especially psilocybin for depression, has been oversold (he wrote about this in Unherd). He pointed to methodological weaknesses, potential conflicts of interest, small sample sizes, weak control groups, and a broader tendency in psychedelic culture to inflate early findings into grand claims.
This is not a frivolous objection. In fact, Matt and I largely agreed with part of it. Psychedelic advocates have often exaggerated the research. There is a real problem of “miracle cure” rhetoric — the idea that someone takes psilocybin once, sees God, and their depression is gone forever. That is not how serious psychedelic therapy works. In my own experience, the medicine is only one part of the process. Preparation, therapy, integration, and continued psychological work matter enormously.
Matt also conceded that some of the depression research has been inflated by trial-design problems. In particular, he explained that large effect sizes in some psychedelic depression studies may partly reflect weak improvement in control groups, not necessarily miraculous improvement in psychedelic groups. Functional unblinding is also a major challenge: participants often know whether they received a psychedelic, making placebo-controlled trials difficult.
But this critique does not defeat the case for the executive order. It strengthens it.
The order does not declare psilocybin approved. It does not legalize psychedelics for general public use. It does not remove FDA review. It accelerates evaluation of compounds that have already shown enough promise to warrant serious study. As Matt put it, the EO is not “the end of prohibition”; it is a set of mechanisms to move research and review forward so that, if FDA approval comes, bureaucracy does not create unnecessary bottlenecks.
Even if psilocybin ultimately proves comparable in average effect size to SSRIs, that could still matter enormously. A treatment with a radically different mechanism may help a different subset of patients — especially those who have cycled through multiple conventional antidepressants without relief. The key argument is not that psilocybin is a magic bullet. It is that serious mental illness is heterogeneous, existing tools are inadequate for many people, and novel mechanisms deserve rigorous evaluation.
The proper response to weak or incomplete studies is not to freeze the field. It is to do better studies.
2. “Ibogaine is dangerous”
Sabet’s strongest substantive concern was around ibogaine’s risks. Unlike classic psychedelics such as psilocybin, ibogaine has a more serious cardiac risk profile. It can prolong the QT interval, raising concerns about potentially dangerous heart rhythms. Sabet warned that federal enthusiasm could understate these risks and give the impression that ibogaine is already proven safe and effective.
This is the objection that deserves the most caution. Ibogaine is not a casual wellness drug. It should not be treated like a retreat-center sacrament or a lifestyle intervention. It is a powerful psychoactive substance with real medical risks.
But Matt’s response was crucial: the risk profile depends heavily on context, screening, and dosing model. Many drugs that affect cardiac markers would be unacceptable as daily medications. But ibogaine, if used at all, would likely be administered a very limited number of times under intensive medical supervision. Patients can be screened beforehand; they can be monitored with EKGs in real time; physicians can have rescue medications available; and higher-risk patients can be excluded.
That does not eliminate the risk. But it changes the policy question.
The real question is not: “Is ibogaine perfectly safe?” It obviously is not. The question is: “For patients with severe addiction, suicidality, PTSD, or treatment-resistant conditions, should carefully monitored clinical research and limited access pathways be available?”
Sabet himself did not fully reject Right to Try. He said that for desperate patients who have tried other options, he would not necessarily stand in the way. His concern was that the public rhetoric around ibogaine may be too celebratory.
That is a fair warning. But it is not an argument against the executive order. It is an argument for strict protocols, careful monitoring, transparent adverse-event reporting, and sober public messaging.
3. “Joe Rogan should not be setting drug policy”
Sabet also objected to the politics of the order. Joe Rogan reportedly played a role in pushing the issue onto Trump’s radar, and Sabet argued that drug policy should be determined by science, not podcasters, popularity, or political access.
On one level, I understand this concern. In an ideal world, medical policy would emerge from careful scientific review, not celebrity advocacy or Oval Office access. But that ideal world does not exist. Policy is always shaped by advocates, donors, patients, researchers, media figures, bureaucrats, and political coalitions.
The relevant question is not whether Rogan had influence. The question is whether the policy he influenced is scientifically reckless.
And on the substance, the order does not approve ibogaine because Joe Rogan likes it. It does not legalize psilocybin because podcasters talk about it. It directs agencies to accelerate research, review, and access pathways for compounds still subject to FDA evaluation. The White House order explicitly centers FDA review, Breakthrough Therapy designations, Right to Try pathways, and rescheduling only after successful clinical development. (The White House)
Matt’s point here was pragmatic: Rogan may have helped put the issue on the president’s radar, but what followed was not FDA approval by podcast. It was an administrative push to evaluate promising therapies more quickly.
I also pointed out that Rogan was not the sole force behind this. Advocates, veterans, researchers, and figures in the MAHA orbit had been pushing psychedelic research and access long before the Oval Office photo-op. Even Sabet conceded Rogan was not the only influence, though he thought Rogan may have been the tipping point.
Science still has to do the work. The data still have to be reviewed. The FDA still has to decide.
4. “This could become another marijuana or ketamine disaster”
Sabet’s broader fear is historical. America has a bad track record with drugs, medicine, and profit. Cannabis was sold as medical before the evidence justified many of the claims. Ketamine clinics exploded in a way that sometimes blurred therapy, consumer wellness, and profit-seeking. Matthew Perry’s death has become a symbol of how even medically useful drugs can be abused in poorly controlled systems.
This was probably Sabet’s most emotionally powerful argument: even if Marty Makary, Jay Bhattacharya, and serious researchers intend to be responsible, systems can be captured. Give industry an inch, and it may take a mile.
Matt did not dismiss this. In fact, he agreed that bad actors will exist. If psychedelics are approved, some people will use them irresponsibly, some clinicians may act recklessly, and some entrepreneurs will try to exploit the field. He specifically warned about the risk of doctors becoming “gurus,” abusing spiritual authority, sleeping with patients, or fleecing vulnerable people.
But again, the answer is not paralysis. The answer is regulation.
This is where psychedelics may have an advantage over cannabis and off-label ketamine. FDA-approved psychedelics would almost certainly come with REMS — Risk Evaluation and Mitigation Strategies — requiring administration in controlled clinical settings, screening, supervision, preparation, and post-session monitoring. Matt emphasized that these guardrails could prevent the “send it home” model that has plagued parts of the ketamine industry.
That is the key distinction. The executive order does not call for dispensary psychedelics. It does not call for at-home ibogaine. It does not call for casual recreational access. Properly implemented, it points toward a medical model: controlled, supervised, clinically evaluated, and restricted to serious conditions.
Critics are right to fear a psychedelic gold rush. But that is precisely why federal agencies should shape the field before underground markets, retreat centers, and loosely regulated clinics do.
5. “The field is full of hype, conflicts, and true believers”
Sabet repeatedly warned that psychedelic research is surrounded by conflicts of interest, Silicon Valley money, ideological zeal, and people who treat these drugs almost religiously. He worried that harms are being minimized and benefits exaggerated.
This is true enough to matter. Psychedelic culture has always attracted utopianism. Some advocates talk as if these compounds will heal trauma, end addiction, create enlightenment, transform politics, and usher in a new era of human consciousness.
Matt was blunt about this: he has met many people who have used psychedelics, but he has “never met an enlightened person.” He also rejected grand claims that psychedelics will produce a new age of universal healing or “net zero trauma.”
That kind of realism is exactly what the field needs. But it is also why Sabet’s critique misses its target. The best defenders of the executive order are not saying psychedelics will save humanity. They are saying that for certain conditions — depression, addiction, PTSD, end-of-life distress — there is enough signal to justify more rigorous trials, faster review, and carefully controlled access for desperate patients.
In fact, more federal research may reduce the influence of true believers. Matt argued that one benefit of facilitating research is that it brings more scientists into the field, including researchers without ideological or financial conflicts. More funding, more scrutiny, and more institutional involvement can widen the field beyond the early adopters and evangelists.
If Sabet is worried about psychedelic science being dominated by enthusiasts, the solution is not less science. It is more science.
The real disagreement
By the end of the conversation, the disagreement became clearer.
Sabet was not mainly objecting to the literal text of the executive order. He acknowledged that some parts — more research, limited Right to Try access, and careful study — are defensible. His deeper concern was cultural and institutional: that America’s addiction-for-profit machinery will transform promising medicines into another loosely regulated commercial drug market.
That concern should be taken seriously. Psychedelic advocates should not sneer at it. The movement has overpromised before. Bad actors exist. Vulnerable patients can be harmed. And ibogaine, in particular, requires intense caution.
But Sabet’s critique ultimately proves too much. If the standard is that a field must be free of hype, conflicts, imperfect studies, political advocacy, and commercial interests before the government can accelerate research, then almost no area of medicine would qualify. Oncology, obesity drugs, Alzheimer’s research, psychiatry — all are shaped by money, politics, urgency, patient desperation, and imperfect evidence.
The relevant standard is not purity. It is whether the government is preserving rigorous review while removing unnecessary barriers.
On that standard, the executive order is defensible. It does not declare psychedelics safe and effective by fiat. It does not bypass the FDA. It does not open the floodgates to recreational use. It says, in effect: these compounds may matter; the mental health crisis is severe; the existing treatment landscape is inadequate; and the federal government should move faster to find out what works.
That is not reckless. It is overdue.
The challenge now is implementation. If the administration uses this order to pressure regulators into ignoring adverse events, critics like Sabet will be vindicated. If companies exploit the moment to build a psychedelic version of the worst ketamine clinics, the backlash will be deserved. If advocates keep speaking in miracle-cure language, they will undermine the very science they claim to support.
But if the result is better trials, more careful access, stricter safety protocols, faster FDA review, and more options for people who have exhausted conventional treatments, then the executive order will be remembered not as a capitulation to drug culture, but as a serious course correction in American mental health policy.
The strongest case against the order is that we are moving too fast.
The stronger answer is that, for millions of suffering patients, we have been moving too slowly — and that urgency and rigor do not have to be enemies.
I Need Your Support!
The Illusion of Consensus is a fully citizen-funded publication. Trips to Washington, D.C to cover important stories don’t happen without your support! If you value the high-quality mental health and wellness journalism on this site, consider becoming a paid or founding member to receive exclusive articles, early-access episodes, and ask questions for future episodes. Or support The Illusion of Consensus with a one-time donation.